REG - Feedback PLC - Notice of Results & Retail Investor Presentation

FeedbackAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260202:nRSB9154Qa&default-theme=true

RNS Number : 9154Q  Feedback PLC  02 February 2026

 

Feedback plc

 

Notice of Interim Results & Retail Investor Presentation

 

Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the clinical
infrastructure specialist, expects to announce results for the half year ended
30 November 2025 on Tuesday 17 February 2026.

 

Investor Presentation: 16:00, Tuesday 17 February

Management will be providing a presentation and hosting an investor Q&A
session on the Company's results and future prospects on Tuesday 17 February
at 16:00. Investors can sign up for free and register to meet FDBK via the
following link:
https://www.investormeetcompany.com/feedback-plc/register-investor
(https://www.investormeetcompany.com/feedback-plc/register-investor)

 

Investors who have already registered on the Investor Meet Company platform to
meet the Company will automatically be invited.

 

 

--Ends--

Enquiries:

 

 Feedback plc                                +44 (0) 20 3997 7634

 Tom Oakley, CEO                             IR@fbk.com (mailto:IR@fbk.com)

 Emma Oswick, CFO

 Panmure Liberum Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd;                            Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                             (mailto:feedbackplc@walbrookpr.com)
 Nick Rome/Marcus Ulker                      07748 325 236 or 07867 984 082

 

 

About Feedback plc

 

Feedback plc is the strategic partner to unlock productivity in health and
care through digital connectivity and asynchronous collaboration. With proven
expertise in system integration, we enable teams to work flexibly, share
information securely, and deliver care more efficiently.

 

Bleepa® is an award-winning collaboration platform that improves the quality
and productivity of patient pathways enabling health and care organisations to
hit targets with their existing clinical workforce. We achieve this by
connecting digital infrastructure across systems, enabling asynchronous
working, reducing geographic barriers and removing unnecessary appointments.

 

Bleepa supports the shift from analogue to digital and from hospital to
community-based care, by uniting essential data and teams to enhance clinical
decision making and enable better coordinated care.

 

The Company has a number of growth opportunities domestically and
internationally across a range of public and private healthcare markets
including the NHS. Our highly scalable software-as-a-service (SaaS) based
model is expected to provide increasing levels of revenue visibility as the
Company grows its customer base.

 

https://fbk.com (https://fbk.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBLMLTMTJTMFF



            Copyright 2019 Regulatory News Service, all rights reserved